Charles Chua, Author at AsiaPEVC.com

Software AG to Power Growth Across APJ with New Senior Executive Hires

Software AG (Frankfurt MDAX: SOW) today announced a number of senior executive appointments in Asia Pacific and Japan (APJ). This forms the cornerstone of the company’s plan to establish a leadership team that can better support its customer and partner bases in the region, underscoring the importance that Software AG is placing on the region. This also follows a robust 1Q21 global business performance, where digital business transformation emerged as a key growth driver for Software AG.

Software AG aims to help organizations become truly connected and turn business data into information that can be acted on. The new appointments collectively boost Software AG’s ability to respond to the evolving needs of organizations in APJ, especially in light of the rapid digitalization in this region.

Nicolas Betbeder-Matibet has been appointed Software AG’s new Senior Vice President of Sales for Asia Pacific and Japan and will lead the region, where he is responsible for driving all regional GTM efforts as well as cultivating a strong culture and purpose for the team in APJ. Nicolas joins the company from Tibco, where he led their Asia business and drove an aggressive regional growth strategy for the company. Nicolas has also held senior roles at MEGA International and CGI Consulting and is a well-known regional speaker.

Software AG veteran Michael Cross has taken on a new role as the Vice President of APJ Alliance and Channels. With renewed focus on alliances and channels to boost Software AG’s business growth in APJ, Cross’ responsibilities also include an important role to shape the company’s IoT Go-To-Market strategy for the region. Based in Australia, Cross’s 11-year tenure at Software AG spanned a number of leadership roles across its APJ operations, providing him with insight into the region’s unique business nuances.

Lorne Fetzek, appointed as Software AG’s Country Manager of Japan, brings with him more than 20 years of experience and a stellar track record in leading technology heavyweights. Lorne started his career with Dell Japan, and has held Japan country-level and APJ regional-level leadership positions at Verizon, Polycom, and Proofpoint. Prior to joining Software AG, Lorne was the Area Vice President, Japan for cybersecurity specialist, Imperva. Lorne is looking forward to utilizing his experience in the Japan market to strengthen Software AG’s growing Japan business.

KyuHwan Lee, Country Manager of Software AG, South Korea, joins the company from Oracle Digital Prime. KyuHwan previously held the role of Sales Director, and was responsible for driving customer-oriented strategies, marketing and sales play with his direct reports and partners for Oracle. These strategies led to outstanding results, achieving remarkable growth for Oracle in FY20 for which he was honored with the “Outstanding FLM in FY20” recognition.

Scott Little, Senior Vice President of Global Sales said: “Our growth momentum over the past quarter has been driven in no small part by the rise of digital business, and bolstering our ranks with industry veterans will position us well to continue building on the strong momentum that we have established. The rapid digitalization of APJ presents new opportunities for Software AG to distinguish itself as a leading industry player by supporting the growth of the region’s digital-first businesses. Led by our newly minted team, we are thrilled to embark on a new chapter of our regional growth story and look forward to further entrenching Software AG’s presence in APJ.”

Moving ahead, Software AG’s approach to growth will be centered around the Helix transformation strategy. Built around the values of “Focus, Team and Execution”, it sets solid, material goals for the company, including targeted, sustainable and profitable growth, and a commitment to medium-term milestones, metrics and pathways.

Earlier in February 2021, Software AG announced a partnership with Singaporean telecommunications company StarHub that aims to help businesses consolidate varied IoT assets on a massive scale via the 5G IoT platform service. It is billed as a one-stop solution that provides IoT connectivity including StarHub’s 5G, device management, professional services to integrate existing or new systems, and managed services to run the entire IoT environment for any organization. This accelerates and adds scalability to IoT implementations, empowering organizations with productivity boosts, enhanced innovation capabilities, as well as overall cost-savings.

About Software AG

Software AG is the software pioneer of a truly connected world. Since 1969, it has helped 10,000+ organizations use software to connect people, departments, systems and devices. Software AG empowers truly connected enterprises using integration & APIs, IoT & analytics and business & IT transformation. Software AG’s products establish a fluid flow of data that allows everything and everyone to work together. The company has more than 4,700 employees across more than 70 countries and annual revenue of over EUR 800m, with the aim of exceeding EUR 1bn by 2023. For more information, visit www.softwareag.com. And follow on LinkedIn and Twitter.

Software AG Media Contact
Jane Chan
E: Jane.Chan@softwareag.com
T: +65-9150-3794

PRecious Communications for Software AG
E: softwareag@preciouscomms.com
T: +65-6303-0567

PallyCon, a Multi DRM and Forensic Watermarking Service for OTT apps, adds App Security to its digital arsenal

PallyCon, a global leader in Multi DRM, forensic watermarking services, and anti-piracy technologies launches its state-of-the-art app security service. The company has now become a robust 360-degree cloud-based end-to-end content security service provider to OTT platforms

A simple plug-n-play solution, it is dedicated to helping content developers and publishers protect their content from manipulation and theft. The solution is conceptualized with no single line of code and offers robust security that’s also highly affordable.

Expressing his thoughts, CEO and Founder at INKA Entworks Inc. James Sungim Ahn said, “With the increasing popularity and rise in viewership of OTT apps, the chances of theft and leakages have increased multiple times. It takes a lot of effort and money to produce content, and illegal access and copying are causing significant revenue losses. Hence, data security should be considered mandatory, and all content creators should adopt 360-degree security along with DRM service for OTT apps to protect their investment”.

“Building an OTT app is no easy feat, it takes a lot of time and energy. And in today’s application-focused world, security can’t slow down your speed of development,” he added.

The solution offers a real-time threat analytics dashboard for content creators to trace the source of piracy and hacking of streaming content in real-time. It works in tandem with a high-performance DRM video protection service to identify leakages right to the last user who leaks or consumes the content illegally, thus offering endless scalable security. The solution supports Android, iOS, and other hybrid apps. Our powerful security suite ensures real-time in-depth application security with features like source code protection, anti-reverse engineering, cheat tool and emulator detection/blocking, while enforcing app integrity. Here are a few ways in which the solution stands out:

A simple plug-n-play solution (Get a secured OTT app in “Minutes“)
Robust security that’s highly affordable
Real-time Threat Analytics Dashboard
No single line of code
Unlimited free trials
Supports Android, iOS and hybrid apps
No annual maintenance charges (AMC), hardware setup or tech support cost
Meet compliance needs with data localization rules
Endlessly scalable security
Content security, App security and data security in a single workflow

Discussing the immense potential of the service Govindraj Basatwar, Head of Global Business for INKA Entworks said, “We are pleased to announce the commencement of our app and data security services. Cyber-attacks against OTT apps and content creators are on the rise. Without adequate security, apps can be easily hacked, which poses a threat to the privacy of data and revenue, and puts the brand image at risk too.”

“PallyCon is a first-of-its-kind cloud service that provides 360-degree security for OTT platforms. With this launch, we aim to create a fearless and thriving environment for all content creators and protect their data from potential threats,” he added.

With new security standards set by Hollywood studios, it becomes critical for OTT platforms to protect their apps in runtime. Additionally, the company is offering unlimited free trials to reap the benefits of app and data security without the need for coding.

About PallyCon

PallyCon is a premium content protection service by INKA ENTWORKS trusted by 200+ customers globally, providing 360-degree, cloud-based end-to-end content security for OTT platforms, such as Multi DRM, Forensic Watermarking, Anti-Piracy services, Anti-Screen capture/recorder, App Security with quick and simple integration. It is an ALL-IN-ONE solution for OTT owners.

About INKA Entworks

INKA Entworks is a pioneer in the field of Digital Rights Management with over 20 years of security experience in providing DRM technology. INKA Entworks holds many patents around DRM and App Security technology. We created cloud-based SaaS platforms (Security as a Service) which offer quick time to market technology services from mobile games and applications to digital streaming, movies, music and online education – which prevent hackers from manipulating or stealing content.

For more information, please contact:
Parag Manikpure
E: parag@inka.co.kr
P: +91 22 6278 5717

Avance Clinical Releases Industry Survey Results at BIO Korea 2021

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical shared results of a recent industry survey conducted by the company that found data quality to be the most important criteria for selecting a CRO for Phase ll studies in Australia.

Results from the survey found 63.64% of respondents selected data quality as the Key operational consideration when planning Phase II, followed by access to patients, then CRO therapeutic area expertise, cost, and access to KOLs.

Avance Clinical is attending BIO Korea 2021 virtually and is available via the Partnering platform to discuss the benefits of conducting trials in Australia. Avance Clinical has extensive experience in conducting trials in oncology, CNS, cardiovascular, infectious diseases and dermatology.

Avance Clinical CEO, Yvonne Lungershausen, said South Korea is recognized globally for its thriving biotech sector and the CRO is keen to connect with companies wanting regional alternatives for their clinical development. “As Australia’s CRO for biotechs, we are seeing an increasing number of South Korean biotechs selecting Australia to accelerate their Phase I and II trials,” she said. “The high-quality of our data for FDA and other regulatory authority approvals is a key factor in the decision-making process.”

The clinical trial environment in Australia supports rapid startup and a rebate of more than 40% on clinical costs as part of the Australian Government’s clinical trial attraction incentive program.

In addition, Avance Clinical is accredited by the Office of the Gene Technology Regulator (OGTR) so it can manage gene technology trials in Australia.

This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs).

Take the Quiz: Test your Knowledge about Australian Clinical Trials here.

About Avance Clinical

Avance Clinical, Australia’s CRO for biotechs, has more than 20-years of experience providing excellence in clinical research services for biotech companies from around the globe. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field. Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class investigators and sites able to access specific patient groups. Visit our website for more information.

Recent Awards:
Excellence in Business Award 2021
Frost & Sullivan Asia-Pacific CRO Market Leadership Award 2020

Other benefits of working with Avance Clinical include:
1. The Government R&D grant offers up to 43.5% rebate on clinical trial spend
2. COVID-19 clinical continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class investigators and sites
7. Access to sites/Phase I facilities with established healthy subject databases and specific patient populations
8. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
9. Seasonal studies: Northern hemisphere sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons

Media Contact:
media@avancecro.com

DIZO – the first brand in the realme TechLife Ecosystem announces its global launch

– DIZO, the global AIoT brand, with ‘Be Different’ as its tagline, promises to bring ‘Smart Tech Life for Every Different You’
– DIZO will focus on entering four major product categories – Smart Entertainment, Smart Home, Smart Care and Accessories
– DIZO comes with realme’s support in 3 key aspects – Industrial Design, Supply Chain and AIoT experience that works perfectly with realme Link
– #DIZO #realmeTechLife #BeDifferent

DIZO, the first brand under the realme TechLife ecosystem, announced its glbal launch today. More than just being a technology brand, DIZO embarks on a philosophy and a journey that aims to empower everyone to enjoy their desired life, enhanced by Smart TechLife. Pronounced as ‘dee-zoe’, the new brand aims to break the clutter of tech similarities and offer solutions that are aligned to the needs of every different consumer. Urging its consumers to “Be Different”, DIZO wishes to offer the technology that complements the individuality of a consumer, empowers them, and becomes an extension of their personalities.

Built around the mission to offer a Smart Tech Life for Every Different You, DIZO along with realme is committed to bringing the best of both brands to its consumers. In fact, DIZO has unflinching support from realme around three key aspects – Industrial Design, Supply Chain and AIoT experience that works perfectly with realme Link.

Congratulating the DIZO team, Madhav Sheth, Vice President, realme and Chief Executive Officer, realme India and Europe said, “This is a momentous occasion as DIZO goes live with its mission to offer innovative and diversified AIoT solutions to its consumers. The new brand will enable consumers to experience a smart, efficient, and interconnected life. Being the first brand in the realme TechLife ecosystem, I am very excited to tell you that DIZO already has great products in the pipeline to offer to its consumers. We wish DIZO good luck and look forward to its success.”

DIZO’s focus is to create a portfolio of an entire range of AIoT solutions that consumers can use in their daily lifestyle. And with that focus in mind, DIZO will enter into four major product categories, which are Smart Entertainment, Smart Home, Smart Care and Accessories for its consumers across the world.

DIZO has seamlessly and efficiently integrated the global supply chain with its local operational resources to meet the varied needs of its consumers. Also, the entire core team members come from global technology brands with stellar experience.

DIZO products will be coming soon to countries in Asia, Europe, North America, South America, Africa, etc. Do follow DIZO for the latest announcements.

Website: www.dizo.net
Facebook: @DIZOTechnology
Twitter: @DIZOTech
Instagram: @dizotech
YouTube: DIZO

ABOUT DIZO

DIZO is a global technology brand and the first brand in the realme TechLife ecosystem. With its brand tagline – ‘Be Different’, DIZO promises to bring ‘Smart Tech Life for Every Different You’. Being the first realme TechLife ecosystem brand, DIZO comes with realme’s support in 3 key aspects – Industrial Design, Supply Chain and AIoT experience that works perfectly with realme Link. In terms of product categories, DIZO will focus on entering into Smart Entertainment, Smart Home, Smart Care and Accessories for its consumers.

Contact for PR queries: pr@dizo.net, Bappi Barman

SOURCE: DIZO

Sweet Expands NFT Marketplace to Shopify Ecosystem

Sweet, the leading enterprise NFT solutions provider, announced the integration of its NFT distribution platform into the Shopify marketplace, empowering brands, shop owners, and IP holders to sell NFTs through existing online store-fronts. The addition of Sweet into the Shopify platform enables global retail and entertainment brands to capitalize on the growing demand for NFTs while keeping consumers in their own branded checkout experience.

According to Tom Mizzone, CEO and founder of Sweet, “To date, NFTs have been primarily sold through third-party crypto marketplaces, forcing brands to make the hard choice of directing consumers to an off-brand experience.

“Additionally, broader consumer bases want to buy and own NFTs but are confused by complex and intimidating blockchain wallet setup, and don’t know how to get started. Now anyone can get into the NFT game through the familiar Shopify checkout experience, furthering Sweet’s commitment to brand partners by prioritizing the consumer experience.”

Sweet’s scalable NFT platform is democratizing NFTs and creating broader ways for retail and consumer brands to offer digital collectables to their users. The ability to sell and distribute through Shopify’s e-commerce platform not only enables direct NFT sales but also enables gamified, bundled, “gift with purchase” NFT experiences with physical merchandise.

“Imagine randomizing and bundling digital assets with t-shirts, vinyl albums, sneaker drops, and more,” said Ken Ellis, CTO of Sweet. “Now imagine gamifying the merch store by hiding Willy-Wonka style golden ticket NFTs in the bundles, surprising and delighting consumers with one-of-a-kind experiences.

“Not only can brands use Sweet’s technology to create engaging consumer experiences, drive sales, and drive profit margins, but the NFT can serve as a cryptographically secure digital certificate of authenticity. The NFTs are publicly verifiable and can’t be counterfeited, and packaging them with physical goods also ensures the authenticity of those goods.”

Sweet’s blockchain-agnostic, eco-friendly NFT solution is bringing digital collectables to the masses by offering retailers flexible distribution options and the ability to mint cost-effective branded NFTs across multiple blockchains. Sweet’s magic is in making these unique digital assets easy for consumers to acquire and receive with no crypto knowledge or expertise needed.

The integration of Sweet’s NFT platform into the Shopify marketplace means that retail brands of all shapes and sizes can now offer NFTs to their consumers in use-cases that are specific and unique to their brand’s aesthetic and personality. According to CNBC, NFT sales in the first quarter of 2021 eclipsed $2 billion. Brands leveraging Sweet’s consumer-first solution are poised to capture a large percentage of sales as NFTs extend into the lives of everyday consumers.

About Sweet

Sweet is the broad-scale enterprise NFT solution taking a user-friendly, consumer-first, eco-conscious approach to digital collectables. Sweet’s blockchain agnostic platform leverages multiple chains, each for the right use-case, allowing Sweet’s enterprise clients to create holistic, long-term NFT strategies that attract both high-end crypto enthusiasts as well as everyday loyal fans. Please visit www.Sweet.io.

Media Contact:

Peter Keiser, EVP of Marketing, Sweet
E: press@sweet.io, Web: https://sweet.io

Distributed for Sweet by Bitcoin PR Buzz (https://bitcoinprbuzz.com).

Agilex Biolabs’ Toxicology Tapped for SARS-CoV-2 Vaccine Research

Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, said biotechs with first-in-human studies can leverage significant quality, speed and cost advantages working with their company TetraQ toxicology for pre-clinical research in Australia.

TetraQ is a NATA-accredited, GLP-recognised rodent toxicology facility.

The TetraQ toxicology team, whose recent COVID-19 vaccine work is featured in PubMed, is one of the most experienced in the region with more than 15 years of success with biotechs and university researchers. In addition, research costs can be offset by 43.5% with the attractive Australian Government clinical research incentive rebate for USA, Asia and European companies.

Agilex Biolabs works closely with Australia’s leading biotech R&D tax rebate specialist, Bentleys R&D Services, to ensure clients are aware of the R&D benefits.

Bentleys’ Managing Director Mike Burfield said the attractive 43.5% R&D rebate on clinical research spend can be applicable for the entire toxicology program.

“The rebate covers rodent toxicology services at TetraQ, while second species toxicology research conducted overseas can also be potentially eligible depending on the company, saving considerable costs in the pre-clinical stage.

Each year we have hundreds of biotech companies from around the world benefiting from this significant refund system operated by The Australian Government to attract clinical research.

However, it is vital that biotechs take advice prior to starting research, and that company documentation is prepared correctly from the start to take full advantage of these savings during the toxicology program, through to phase I and beyond.”

TetraQ toxicology, which was acquired by Agilex Biolabs earlier this year, started in 2005 based out of the University of Queensland and has since earned a strong global reputation for excellence in GLP rodent pre-clinical safety studies.

Agilex Biolabs CEO, Jason Valentine said:“Biotech clients are discovering the considerable speed and cost advantages of using an Australian-based toxicology facility like TetraQ.”The 43.5% rebate on toxicology costs is a major benefit, but clients are also keen to then leverage the easy and rapid transition to first-in-human trials available in Australia. Australia is known as the ideal early-phase destination because of the many regulatory and cost advantages – and most importantly that clinical data is accepted by the FDA and other major authorities.

TetraQ’s NATA-accredited, GLP-recognised rodent toxicology facility is highly regarded for its personalized service, rapid response, and innovative solutions for biotechs planning their first-in-human studies.”

TetraQ non-GLP toxicology study results can be used to support the design of both key efficacy studies and formal GLP toxicology studies in rodents. Formal GLP toxicity studies can in turn support first-in-human studies. GLP studies employ a test item manufactured under Good Manufacturing Practice (GMP) and a study design informed by non-GLP exploratory toxicity studies as well as the intended clinical use. GLP studies are subject to Quality Assurance (QA) audit, as their results are intended to facilitate the safe design of clinical studies.

The study management and data collection processes are supported by an FDA 21 CFR Part 11-compliant Provantis software system. Furthermore interim and final report preparation is also facilitated by this centralized data collection system to allow rapid delivery of written reports to clients.

Agilex Biolabs has more than 120 staff which includes 85 dedicated laboratory staff and supports client pharma and biotech companies from the US, Europe and APAC.

The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilizing the two platforms of LC-MS/MS and Immunoassay.

Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.

Book a confidential briefing with our scientists before you start your next clinical trial.

About Agilex Biolabs

Agilex Biolabs, Australia’s leading bioanalytical and toxicology laboratory, has more than 24 years of experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. It has successfully supported hundreds of preclinical and clinical trials from around the world where customers choose Australia for the streamlined regulatory process and access to the world’s most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.

Agilex Biolabs has the leading certifications including OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition. The company has recently acquired TetraQ biolabs and toxicology, and also expanded its main labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the new lab video walkthrough here.

Agilex Biolabs specializes in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilizing LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flows cytometry (BD FACSymphony A3, 20 color cell analyzer).

Agilex offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:

Immunophenotyping
Receptor occupancy
Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
PBMC assays and cellular mechanism of action assays

Agilex Biolabs Media Contact:
Kate Newton
Media@AgilexBiolabs.com

Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.

Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR).

This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs).

In Australia, dealings with GMOs in clinical research require authorization under the Gene Technology Act 2000. The OGTR administers the Gene Technology Act 2000, and has specific responsibility to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating dealings with GMOs.

The global market for genetic modification therapies is expected to grow from $2.3 billion in 2018 to reach $17.4 billion by 2023, growing at a compound annual growth rate of 49.9% (BCC Research, 2018). The utilization of gene modification technologies used in COVID-19 vaccine products is likely to translate in further growth in this field of therapeutics.

Avance Clinical CEO Yvonne Lungershausen said OGTR accreditation is important for our international clients. “Our clients need to know that their CRO has all the necessary credentials and is capable of delivering the highest of clinical research standards in this exciting and rapidly evolving sector,” she said.

Avance Clinical currently has a number of GMO studies underway and is expanding its services further to accommodate increasing global demand.

Take the Quiz: Test your Knowledge about Australian Clinical Trials here. https://www.surveymonkey.com/r/Australian-Clinical-Trials

About Avance Clinical

Australia’s Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field. Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Visit http://www.avancecro.com for more information.

Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons

Media Contact:
media@avancecro.com

Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results

Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today congratulated client Bionomics Limited (Bionomics) on its positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210.

Liz Doolin, Bionomics’ Vice President Clinical Development commented that “We greatly value our long-standing partnership with Agilex Biolabs who continue to be a partner of choice for Bionomics and have supported the development of BNC210 from the beginning. We look forward to continuing this partnership into the future.”

Bionomics (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), is a global, clinical-stage biopharmaceutical company. Bionomics said in their announcement:

“BNC210 is a novel, negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor in development for the treatment of anxiety and stressor-related disorders, and in November 2019 was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of Post-Traumatic Stress Disorder (PTSD).

The 7-day dosing PK study in ten healthy volunteers (females and males) demonstrated that at a dose of 900 mg given twice daily, the tablet formulation of BNC210 had steady-state 12-hourly exposure levels ranging from 33-57 mg.h/L which exceed the 12-hourly blood exposure of ~25 mg.h/L predicted as necessary to meet the primary endpoints for effectiveness for treating PTSD patients in future clinical trials.

Dr. Errol De Souza, Executive Chairman of Bionomics said, “We are extremely pleased with the results of the 7-day PK study which demonstrate that we reach steady-state levels on the second day following the start of twice-daily dosing and that we not only meet but exceed the blood exposure predicted from the pharmacometrics analysis as necessary for future trials.

“With the dose now selected, we can initiate manufacturing of the tablets, clinical site selection and regulatory filings in preparation for a Phase 2b trial with BNC210 in PTSD patients projected for mid-2021.”

Dr Kurt J. Sales Agilex Biolabs’ Director Immunoassay said: “Anxiety and stress-related disorders have a major impact on the health and wellbeing of hundreds of thousands of Australians with more than 1 in 4 people reported to be impacted by these disorders. The effects of stress and anxiety not only impact a person’s psychological well-being but also their physical well-being and productivity which in turn has a tremendous impact on the economy.

“Novel treatments such as BNC210 are essential weapons in the fight against anxiety and stress-related disorders. Agilex Biolabs has been working closely with Bionomics for several years, supporting the PK regulated Bioanalysis of BNC210 and is privileged to be a part of this potential new treatment for anxiety and stressor-related disorders.”

Agilex Biolabs’ world-class laboratories feature state-of-the-art equipment including Gyrolab Xplore, MSD Quickplex 120, Luminex Magpix, BD FACSymphony A3 flow cytometer and soon to be released, digital droplet quantitative real-time RT-PCR. The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilizing the two platforms of LC-MS/MS and Immunoassay.

Clients can also access a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program. Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity. Agilex Biolabs has more than 100 staff which includes 75 dedicated laboratory staff and supports client pharma and biotech companies from US, Europe and APAC.

Book a confidential briefing with our scientists before you start your next clinical trial.

About Agilex Biolabs

Agilex Biolabs, Australia’s leading bioanalytical laboratory, has more than 24 years’ experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. We have successfully supported hundreds of preclinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and access to the world’s most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.

Agilex Biolabs has the leading certifications including OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition. The company has recently expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the new lab video walkthrough here: https://youtu.be/WNdPGkdr9FA

Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilizing LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
– Immunophenotyping
– Receptor occupancy
– Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
– PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs media contact:
Kate Newton
Media@AgilexBiolabs.com

KONE Redefines the Future of Smart City in Singapore with its DX Class Elevators — the World’s First Elevator Series with built-in Digital Connectivity

KONE, a global leader in the elevator and escalator industry, recently hosted a Customer Experience event in Singapore to showcase the world’s first digital elevator series. The Customer Experience event was held on 22 April 2021 at the National Gallery of Singapore. This was supported by key innovative partners such as Gaussian Robotics, Habitap, G Element and Blindsquare, to bring new user experiences to life through a combination of design, technology, new materials, apps and services.

Aimed at supporting Singapore’s vision to be a sustainable smart city through enhanced eco-efficiency, performance, and aesthetics, KONE DX Class elevators have built-in connectivity as standard. KONE DX Class revolutionizes the role of elevators in future smart buildings: the elevator is no longer merely a way to travel between floors, but an integral and integrated platform that offers intuitive, ambient and connected experiences that extend from the lobby throughout the building. For KONE customers such as infrastructure developers and building owners, a key advantage is the ability to have access to future-proof solutions, where elevator experiences are adapted and upgraded for different needs.

“We are excited to introduce the world’s first digitally-connected elevators — enhancing building value along with our larger ecosystem of partners in the region,” says Mikko Bjork, Managing Director, KONE Singapore. “Not only does the DX Class elevator series bring convenience to customers and users, it also offers a chance for us to secure a green, liveable, and sustainable city for future generations to live in.”

The new KONE DX Class enables customers to tailor and plug in additional software and services for elevators throughout the entire lifetime of a building. By using open application programming interfaces (APIs), KONE’s approach makes it easy to manage and integrate different devices, apps and services with new and existing systems. For elevator passengers this brings a host of new, multisensory experiences inside the elevator, combining physical hardware and digital services. These can be customized according to individual needs and preferences, bringing new levels of ease and convenience.

“We have been working with KONE on distinct, cutting-edge lift integration capabilities that use autonomous cleaning robots to navigate and clean multiple floors in a building by itself,” says Kevin Lee, Business Development Director Gaussian Robotics. “The goal is to always provide a safe and clean work environment for tenants and employees in the building.”

Every KONE DX Class elevator provides:

The option for customers to easily and remotely activate digital services when they need to, including KONE 24/7 Connected Services and KONE Residential Flow.
Secure APIs for third-party solutions, which create new and exciting services. KONE is also announcing agreements with a number of companies, such as Blindsquare; Gaussian Robotics; Habitap; G Element; and more, to bring new levels of sophistication to the people flow experience.
A whole new variety of design options and innovations, including anti-stain, anti-scratch, and anti-bacterial surfaces.
Advanced dynamic display, sound and lighting options to transform the ambianceazx and interior.
A range of sustainable materials to meet green building criteria like BREEAM and LEED.

“KONE is merging technologies of today with existing infrastructure to create smarter and more intelligent buildings — supporting the growth of sustainable cities with a purpose,” says Samer Halabi, Executive Vice President of KONE APAC. “Combining new products and services over the lifetime of a building can be very powerful, and the KONE DX Class makes elevator journeys more enjoyable and sustainable.”

The new KONE DX Class elevator series is ideal for customers looking to modernise existing equipment with enhanced eco-efficiency, performance, and aesthetics. The KONE DX Class will replace the current KONE elevator range.

Read more:
Read more about KONE DX Class elevators: https://www.kone.com/en/products-and-services/elevators-escalators-automatic-doors/kone-dx-class-elevators.aspx
For images and videos, visit KONE’s Material Bank: https://materialbank.kone.com/content/kone-material-bank/search_page.html
Watch the mind-controlled elevator video: https://youtu.be/kUHl9MhgA6M
Connecting more than floors to tickle your senses: https://www.kone.com/en/news-and-insights/stories/connecting-more-than-floors-to-tickle-your-senses.aspx

About KONE

At KONE, our mission is to improve the flow of urban life. As a global leader in the elevator and escalator industry, KONE provides elevators, escalators and automatic building doors, as well as solutions for maintenance and modernization to add value to buildings throughout their life cycle. Through more effective People Flow(R), we make people’s journeys safe, convenient and reliable, in taller, smarter buildings. In 2020, KONE had annual sales of EUR 9.9 billion, and at the end of the year over 60,000 employees. KONE class B shares are listed on the Nasdaq Helsinki Ltd. in Finland. www.kone.com

balabala X Tmall Super Brand Day “Endless Dreams” Super Show during Shanghai Fashion Week

balabala x Tmall Super Brand Day “Endless Dreams” Super Show scored a super success last week in Shanghai. balabala is the first children’s clothing brand to join forces with Tmall Super Brand Day, balabala x Tmall achieving record sales of US$26.9 million during the event (9-12 April), with US$5.7 million on a single day on Tmall. Activities across Balabala’s 4,000+ stores on the Chinese Mainland and Hong Kong joined those at the official Tmall store and live broadcast platforms.

The highlight of the event was the fashion Super Show presented with Shanghai Fashion Week entitled Endless Dreams, celebrating balabala’s vision of inspiring children to explore their innate curiosity and their infinite dreams. A runway show in three chapters, Endless Dreams was presented in the Shanghai Children’s Art Theatre on April 9, making perfect use of the circular structure of the building, transforming the four stories and 10,000 sq.m into a childlike dream planet.

Each chapter unveiled a new collection: balabala x China Mars Mission Collection, balabala x Suzhou Museum Collection, and balabala x Jason Wu Collection, in collaboration with the renowned Taiwanese-Canadian designer and his JW line. 60 unique designs inspired by history took the audience across the universe through time and space, experiencing Endless Dreams. Jason Wu recorded a video of the event to express the design concept personally.

The success of Super Brand Day was driven by balabala’s strategic omnichannel approach. Influenced by the epidemic, balabala quickly responded by strengthening coordinated development of e-commerce platforms, accelerating O2O omnichannel integration, and building a new retail model with enhanced consumer reach across the region – while maintaining sales and growth momentum.

Through Endless Dreams, balabala set new records for innovation in the kidswear industry in several aspects: The first cross-sector co-branding cooperation with three major IPs in the field of kidswear, the first KIDSWEAR External Show during Shanghai Fashion Week, and the first all-age kidswear brand with Tmall Super Brand Day. The Endless Dreams Super Show attracted over 1.2 billion views on ‘Weibo’, China’s No.1 social media platform.

About balabala

balabala is the No.1 kidswear retailer in Asia, providing quality fashion, shoes and accessories for children aged 0-14. The Zhejiang Semir Garment brand delivers high-quality kidswear to children around the world with over 4,000 stores in mainland China and rapid international expansion through a franchising network in Saudi Arabia, Vietnam, Mongolia, Indonesia and Nepal, and direct operations in Hong Kong. balabala grows with a new generation of families, enabling children of the world to experience a wonderful childhood. For details please see https://www.balabala.com.hk/pages/franchisee.

Media contact:

Lucy Lu, luxin@semir.com
Zhejiang Semir Garment Co Ltd
Web: https://www.balabala.com.hk/pages/franchisee

SOURCE: Zhejiang Semir Garment Co Ltd